Barclays PLC Has $590,000 Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Barclays PLC boosted its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 1,275.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,993 shares of the biopharmaceutical company’s stock after acquiring an additional 13,903 shares during the period. Barclays PLC’s holdings in Xenon Pharmaceuticals were worth $590,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in XENE. Y Intercept Hong Kong Ltd lifted its position in shares of Xenon Pharmaceuticals by 68.8% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 24,557 shares of the biopharmaceutical company’s stock worth $967,000 after purchasing an additional 10,007 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Xenon Pharmaceuticals by 0.4% during the third quarter. Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company’s stock worth $151,317,000 after buying an additional 15,226 shares during the last quarter. Two Sigma Advisers LP boosted its position in shares of Xenon Pharmaceuticals by 31.0% in the third quarter. Two Sigma Advisers LP now owns 273,700 shares of the biopharmaceutical company’s stock valued at $10,776,000 after acquiring an additional 64,800 shares during the period. State Street Corp grew its stake in shares of Xenon Pharmaceuticals by 13.2% in the third quarter. State Street Corp now owns 279,513 shares of the biopharmaceutical company’s stock worth $11,004,000 after acquiring an additional 32,701 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in Xenon Pharmaceuticals by 144.2% during the third quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock worth $100,506,000 after acquiring an additional 1,507,135 shares during the period. 95.45% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Xenon Pharmaceuticals

In related news, CFO Sherry Aulin sold 18,709 shares of the stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Gary Patou sold 4,891 shares of Xenon Pharmaceuticals stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $41.08, for a total value of $200,922.28. Following the completion of the transaction, the director now owns 23,573 shares of the company’s stock, valued at approximately $968,378.84. The trade was a 17.18 % decrease in their position. The disclosure for this sale can be found here. 5.52% of the stock is owned by insiders.

Xenon Pharmaceuticals Trading Up 1.7 %

XENE stock opened at $39.20 on Thursday. The firm has a market cap of $2.99 billion, a P/E ratio of -13.90 and a beta of 1.19. Xenon Pharmaceuticals Inc. has a 1-year low of $35.53 and a 1-year high of $50.99. The business’s 50 day moving average is $41.22 and its 200-day moving average is $40.52.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.01. During the same period in the prior year, the firm earned ($0.73) earnings per share. Sell-side analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on XENE shares. Needham & Company LLC reissued a “buy” rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Raymond James reiterated an “outperform” rating and issued a $50.00 target price on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Thursday, December 12th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $56.00.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.